Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,063,907
  • Shares Outstanding, K 96,895
  • Annual Sales, $ 30 K
  • Annual Income, $ -54,370 K
  • 60-Month Beta 0.87
  • Price/Sales 36,141.83
  • Price/Cash Flow N/A
  • Price/Book 4.47
Trade SPRY with:

Options Overview Details

View History
  • Implied Volatility 77.54% ( +13.05%)
  • Historical Volatility 64.64%
  • IV Percentile 25%
  • IV Rank 31.49%
  • IV High 200.62% on 09/19/23
  • IV Low 20.97% on 06/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 326
  • Volume Avg (30-Day) 449
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 12,504
  • Open Int (30-Day) 12,396

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.16
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.89 +39.16%
on 06/27/24
11.90 -7.73%
on 07/15/24
+2.90 (+35.89%)
since 06/26/24
3-Month
7.55 +45.43%
on 06/25/24
11.90 -7.73%
on 07/15/24
+2.63 (+31.50%)
since 04/26/24
52-Week
2.55 +330.59%
on 09/20/23
11.90 -7.73%
on 07/15/24
+3.98 (+56.86%)
since 07/26/23

Most Recent Stories

More News
Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday

The company received a Complete Response Letter from the FDA regarding its lead therapy.

SPRY : 10.98 (-1.88%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such...

SPRY : 10.98 (-1.88%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such...

SPRY : 10.98 (-1.88%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such...

SPRY : 10.98 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 11.65
2nd Resistance Point 11.50
1st Resistance Point 11.24
Last Price 10.98
1st Support Level 10.82
2nd Support Level 10.67
3rd Support Level 10.41

See More

52-Week High 11.90
Last Price 10.98
Fibonacci 61.8% 8.33
Fibonacci 50% 7.22
Fibonacci 38.2% 6.12
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar